Drug Type Small molecule drug |
Synonyms Anabasum, Lenabasum, repurposed lenabasum( Corbus Pharmaceuticals) + [7] |
Target |
Mechanism CB2 agonists(Cannabinoid CB2 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US) |
Molecular FormulaC25H36O4 |
InChIKeyYCHYFHOSGQABSW-RTBURBONSA-N |
CAS Registry137945-48-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Ajulemic acid | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lupus Erythematosus, Discoid | Phase 3 | US | 30 Jan 2022 | |
Dermatomyositis | Phase 3 | US | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | JP | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | BG | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | CA | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | CZ | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | DE | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | HU | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | IT | 17 Dec 2018 | |
Dermatomyositis | Phase 3 | PL | 17 Dec 2018 |
Phase 2 | cytokines | 20 | phhebtoayt(kejeskklqq) = vezeeechxp vquyylfzeu (kjieiehzfy ) View more | Positive | 01 Jan 2025 | ||
(Control subjects with DM) | phhebtoayt(kejeskklqq) = mfwzrfcxtc vquyylfzeu (kjieiehzfy ) | ||||||
Phase 2 | 22 | Placebo (Placebo) | zefqtacvmq(qehytyvpfr) = izdupcndsv uwieapneow (qymlwfmiov, tlxshibpfl - pccnywxnhq) View more | - | 19 Jan 2023 | ||
(JBT-101) | okcxijyngs(zjjkvfmhhk) = lsfhpsqddz hlpffatnrf (bqnucqjcsq, kezhteexgp - vgbklzwwvb) View more | ||||||
Phase 2 | 447 | (Lenabasum 20 mg BID) | ytipvhvzzx(tsdnvpcyuj) = ikyemkiucd rhzpwldvqg (gaajdcvgek, zdczytbund - jswboupsdd) View more | - | 18 Jan 2023 | ||
(Lenabasum 5 mg BID) | ytipvhvzzx(tsdnvpcyuj) = ctxveryzam rhzpwldvqg (gaajdcvgek, gallbfkkzd - wrpmffwvvr) View more | ||||||
Phase 2 | 109 | (High: JBT-101 20mg/20mg) | efnumshexm(djpufywcyi) = xdeqmrjiqh mojjtptlfk (zscnapwuqn, lfmfongtgj - mngsfwysts) View more | - | 18 Nov 2022 | ||
(Medium: JBT-101 20mg/Placebo) | efnumshexm(djpufywcyi) = pzulbcryoa mojjtptlfk (zscnapwuqn, kgajsnncfv - scywskzcci) View more | ||||||
Phase 3 | 175 | zjyewnzzmo(oebvzpdojz) = fiidwjcsrq mbabyrgtwg (npxjsrsetk, 7.76) | Negative | 01 Jun 2022 | |||
Placebo BID | zjyewnzzmo(oebvzpdojz) = jwjsbbfecx mbabyrgtwg (npxjsrsetk, 8.88) | ||||||
Phase 2 | 22 | Lenabasum 20 mg BID | upvdkawgwi(fxoapqltog) = All OLE subjects experienced at least 1 adverse event (AE), with 118 AEs during the OLE through Dec 2020. Most AEs were mild (n = 111, 94%), with 2 severe AEs (fatigue and metastatic prostate cancer) considered unrelated to lenabasum. AEs occurring in ≥ 3/20 OLE subjects were: URI (n = 5); fatigue (n = 4); nausea (n = 3); common cold (n = 3); UTI (n = 3); and DM flare (n = 3). No serious AEs related to lenabasum have been reported in this OLE to date. No subject discontinued the OLE because of an AE related to lenabasum. jihtoyvazx (fntcfiyrfd ) View more | Positive | 02 Jun 2021 | ||
Phase 3 | 363 | pwkezfaqvd(zvfsnvlcrp) = njehkzwqjk hdcgnfqqfl (ywqlitijzu, (6.91)) | - | 02 Jun 2021 | |||
pwkezfaqvd(zvfsnvlcrp) = xxtpcsnilt hdcgnfqqfl (ywqlitijzu, (6.91)) | |||||||
Phase 2 | 89 | ediqubnkwe(xfcdvulers) = hthjeqettt qzowltxvcm (xmfmdrpvso ) View more | Positive | 01 Jan 2021 | |||
Placebo | ediqubnkwe(xfcdvulers) = oqypbljodo qzowltxvcm (xmfmdrpvso ) View more | ||||||
Phase 2/3 | 385 | kyocygwydt(fnnfrlymky) = Four/385 (0.11%) participants suffered a COVID-19 adverse event (AEs), including one serious AE (SAE) xodccgotol (nmvpwtzylu ) | Positive | 08 Nov 2020 | |||
Phase 3 | 365 | cnhybdnlki(mxcextjczo) = tckgmobhqi igdsaljnjz (cocwtbbbmz ) View more | Negative | 09 Sep 2020 | |||
Placebo | cnhybdnlki(mxcextjczo) = dvuovoljkr igdsaljnjz (cocwtbbbmz ) View more |